Literature DB >> 4750455

Intravenous infusions of heparin and penicillins.

J Jacobs, D Kletter, E Superstine, K R Hill, B Lynn, R A Webb.   

Abstract

The chemical stability and anticoagulant activity of heparin (20 U/ml) were studied in five intravenous fluids at room temperature. Heparin remained stable and active for 24 hours in normal saline, but there was a rapid inactivation of 40 to 55% in solutions containing dextrose or lactate, as measured by chemical and biological methods.High concentrations of benzylpenicillin, ampicillin, or methicillin had no effect on heparin activity in normal saline or dextrose 5%: nor was the stability of the penicillins in these fluids affected to any marked extent by the presence of heparin. Ampicillin was, however, found to be unstable in dextrose 5%, and it would be preferable for it not to be added to dextrose infusions. It is concluded that heparin may be given intravenously in normal saline with benzylpenicillin, ampicillin, or methicillin but several other antibiotics were found to be unsuitable for concurrent infusion with heparin.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4750455      PMCID: PMC477874          DOI: 10.1136/jcp.26.10.742

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  8 in total

1.  STABILITY OF HEPARIN SOLUTIONS.

Authors:  J PRITCHARD
Journal:  J Pharm Pharmacol       Date:  1964-07       Impact factor: 3.765

2.  Portable heparin injector.

Authors:  J O'Riordan; W MacGowan
Journal:  Lancet       Date:  1970-09-05       Impact factor: 79.321

3.  Portable heparin injector.

Authors:  A J Handley
Journal:  Lancet       Date:  1970-08-08       Impact factor: 79.321

4.  Stability of sodium ampicillin in aqueous solutions.

Authors:  P K Hiranaka; A G Frazier; J F Gallelli
Journal:  Am J Hosp Pharm       Date:  1972-04

5.  Inactivation of penicillins by carbohydrate solutions at alkaline pH.

Authors:  M S Simberkoff; L Thomas; D McGregor; I Shenkein; B B Levin
Journal:  N Engl J Med       Date:  1970-07-16       Impact factor: 91.245

6.  Heparin in acid solutions.

Authors:  S L Stock; N Warner
Journal:  Br Med J       Date:  1971-07-31

7.  Intravascular coagulation and E. coli septicaemia.

Authors:  F E Preston; R G Malia; M J Sworn; E K Blackburn
Journal:  J Clin Pathol       Date:  1973-02       Impact factor: 3.411

8.  Dextrose and sorbitol as diluents for continuous intravenous heparin infusion.

Authors:  J M Chessells; T A Braithwaite; D A Chamberlain
Journal:  Br Med J       Date:  1972-04-08
  8 in total
  8 in total

1.  Anticoagulant activity of heparin in intravenous fluids.

Authors:  T Okuno; C A Nelson
Journal:  J Clin Pathol       Date:  1975-06       Impact factor: 3.411

2.  Adverse reactions following intravenous penicillin-G relate to degradation of the drug in vitro.

Authors:  K A Neftel; M Wälti; H K Schulthess; J Gubler
Journal:  Klin Wochenschr       Date:  1984-01-02

3.  Stability of heparin in intravenous fluids.

Authors:  G A Shah; T Z Dhall; I A Ferguson; M R Davis; D P Dhall
Journal:  J Clin Pathol       Date:  1980-12       Impact factor: 3.411

4.  Stabilized infective endocarditis and altered heparin responsiveness during cardiopulmonary bypass.

Authors:  Sungwon Na; Jae Kwang Shim; Duk-Hee Chun; Dae Hee Kim; Seong Wook Hong; Young-Lan Kwak
Journal:  World J Surg       Date:  2009-09       Impact factor: 3.352

5.  Heparin stability: effects of diluent, heparin activity, container, and pH.

Authors:  K T Goodall; C C Chooi; A S Gallus
Journal:  J Clin Pathol       Date:  1980-12       Impact factor: 3.411

Review 6.  Antithrombotic drugs: part I.

Authors:  A S Gallus; J Hirsh
Journal:  Drugs       Date:  1976       Impact factor: 9.546

7.  Heparin 1986. Indications and effective use.

Authors:  P Ockelford
Journal:  Drugs       Date:  1986-01       Impact factor: 9.546

8.  Heparin does not modify plasma daunomycin disappearance in acute leukaemia patients.

Authors:  E Piazza; S Cortellazzo; L Ottolenghi; A Poggi; T Barbui; M B Donati
Journal:  Br J Cancer       Date:  1980-11       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.